Phaseline

Companies › HK inno.N

HK inno.N: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Cardiovascular, Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IN-115314 Ointment–Phase 2Mild to Moderate Atopic Dermatitis–
IN-G00002–Phase 1Non-valvular Atrial Fibrillation (NVAF)–
IN-R00002–Phase 1Non-valvular Atrial Fibrillation (NVAF)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06725355IN-G00002Phase 1Non-valvular Atrial Fibrillation (NVAF)CardiovascularOct 2024
NCT06725355IN-R00002Phase 1Non-valvular Atrial Fibrillation (NVAF)CardiovascularOct 2024
NCT07073677IN-115314 OintmentPhase 2Mild to Moderate Atopic DermatitisImmunologyJul 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Neurimmune CuraSen Therapeutics Seismic Pharmaceuticals Operations Tectonic Operating Company Foresee Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.